JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 26, 2003; DOI: 10.1124/jpet.103.053686


0022-3565/03/3063-1210-1218$20.00
JPET 306:1210-1218, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.053686v1
306/3/1210    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hines, R. N.
Right arrow Articles by McCarver, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hines, R. N.
Right arrow Articles by McCarver, D. G.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Genetic Variability at the Human FMO1 Locus: Significance of a Basal Promoter Yin Yang 1 Element Polymorphism (FMO1*6)

Ronald N. Hines, Zhaohui Luo, Kathleen A. Hopp, Erwin T. Cabacungan, Sevasti B. Koukouritaki, and D. Gail McCarver

Department of Pediatrics, Birth Defects Research Center and Department of Pharmacology/Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin

The flavin-containing monooxygenases (FMOs) are important for the disposition of a variety of toxicants, therapeutics, and dietary components. Although FMO1 is the dominant isoform in fetal liver and adult kidney and intestine and despite up to a 10-fold intersubject variation in expression, a paucity of information is available on FMO1 genetic variability. To address this issue, 24 samples from the Coriell DNA Polymorphism Discovery Resource Panel were sequenced revealing 10 common single nucleotide polymorphisms (SNPs): four located upstream of the structural gene; three within exonic sequences; one within the intron 1 splice donor site; and two with the 3'-untranslated region. Six of these variants are novel. Compared with other FMO loci within the chromosome 1q23-25 cluster, FMO1 seems more highly conserved. Of the identified FMO1 SNPs, only a C>A transversion 9,536 base pairs upstream of the exon 2 ATG start codon (g.-9,536C>A) would likely affect function, because it lies within the conserved core binding sequence for the yin yang 1 (YY1) transcription factor. Electrophoretic mobility shift assays demonstrated that the g.-9,536C>A transversion eliminated YY1 binding. Furthermore, data from transient expression assays in HepG2 cells suggested this SNP could account for a 2- to 3-fold loss of FMO1 promoter activity. Genotype analysis revealed a g.-9,536A allele (FMO1*6) frequency of 13 and 11% in African- and northern European-Americans, respectively, but a significantly higher frequency of 30% in Hispanic-Americans. Thus, the FMO1*6 variant may account for some of the observed interindividual variation in FMO1 expression.


Received April 30, 2003; accepted June 6, 2003.

Address correspondence to: Dr. Ronald N. Hines, Department of Pediatrics, Birth Defects Research Center, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee WI 53226-4801. E-mail: rhines{at}mail.mcw.edu




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
G. Rodriguez-Fuentes, R. Aparicio-Fabre, Q. Li, and D. Schlenk
Osmotic Regulation of a Novel Flavin-Containing Monooxygenase in Primary Cultured Cells from Rainbow Trout (Oncorhynchus mykiss)
Drug Metab. Dispos., July 1, 2008; 36(7): 1212 - 1217.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. D. Shadley, K. Divakaran, K. Munson, R. N. Hines, K. Douglas, and D. G. McCarver
Identification and Functional Analysis of a Novel Human CYP2E1 Far Upstream Enhancer
Mol. Pharmacol., June 1, 2007; 71(6): 1630 - 1639.
[Abstract] [Full Text] [PDF]


Home page
GeneticsHome page
R. D. Houston, C. S. Haley, A. L. Archibald, N. D. Cameron, G. S. Plastow, and K. A. Rance
A Polymorphism in the 5'-Untranslated Region of the Porcine Cholecystokinin Type A Receptor Gene Affects Feed Intake and Growth
Genetics, November 1, 2006; 174(3): 1555 - 1563.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. Zhang and J. R. Cashman
QUANTITATIVE ANALYSIS OF FMO GENE mRNA LEVELS IN HUMAN TISSUES
Drug Metab. Dispos., January 1, 2006; 34(1): 19 - 26.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. B. Koukouritaki, M. T. Poch, E. T. Cabacungan, D. G. McCarver, and R. N. Hines
Discovery of Novel Flavin-Containing Monooxygenase 3 (FMO3) Single Nucleotide Polymorphisms and Functional Analysis of Upstream Haplotype Variants
Mol. Pharmacol., August 1, 2005; 68(2): 383 - 392.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
B. Furnes and D. Schlenk
Evaluation of Xenobiotic N- and S-Oxidation by Variant Flavin-Containing Monooxygenase 1 (FMO1) Enzymes
Toxicol. Sci., April 1, 2004; 78(2): 196 - 203.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.